Grants per year
Personal profile
Research Interests
My primary clinical interest is in infections in immunocompromised patients, including stem cell and solid organ transplant recipients. I am involved in numerous clinical trials involving anti-infectives, in both the immunocompromised population and in situations involving other pediatric infections. I also study the pathogenesis of viral encephalitis, using models which focus on host-pathogen interactions in neurologic disease due to herpes simplex virus in newborns.
Transplant infectious diseases; Infections in immunocompromised pediatric patients
Certifications and Licenses
| Pediatric Infectious Diseases | |
| Pediatrics |
Training Experience
| 2004 | Residency, University of Colorado Health Science Center |
| 2007 | Fellowship, University of Washington School of Medicine |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Emory University
… → 2001
PhD, University of Pennsylvania
… → 1991
Research interests keywords
- Brain and Nervous System
- Clinical Research
- HIV Infection
- Immunodeficiency
- Immunology
- Infectious Diseases
- Infectious Diseases in Children
- Newborn Infants
- Transplantation
- Virus Diseases
Fingerprint
Dive into the research topics where William J Muller is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
NAB-BC-3781-1202: A Phase 1, Open-Label, Two-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Intravenous Lefamulin in Hospitalized Pediatric Subjects Receiving Standard of Care Antibiotic Therapy for Confirmed or
Muller, W. J. (PD/PI)
Nabriva Therapeutics Ireland DAC
6/11/20 → 8/31/50
Project: Research project
-
Consultation of Influenza Trial Design for Immuno-Compromised Pediatric Subjects
Muller, W. J. (PD/PI)
11/22/19 → 8/31/50
Project: Research project
-
A pilot recruitment strategy to enhance ethical and equitable access to Covid-19 pediatric vaccine trials
Muller, W. J., Jhaveri, R., Heald-Sargent, T., Macy, M. L., Heard-Garris, N., Shah, S. & Paquette, E., Jun 2024, In: Clinical Trials. 21, 3, p. 390-396 7 p.Research output: Contribution to journal › Article › peer-review
-
Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population
Maglalang, P. D., Sinha, J., Zimmerman, K., McCann, S., Edginton, A., Hornik, C. P., Hornik, C. D., Muller, W. J., Al-Uzri, A., Meyer, M., Chen, J. Y., Anand, R., Perrin, E. M. & Gonzalez, D., 2024, (Accepted/In press) In: Clinical Pharmacokinetics.Research output: Contribution to journal › Article › peer-review
-
Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies
Fisher, B. T., Blumenstock, J., Boge, C. L. K., Shuster, S., Seif, A. E., Green, M., Michaels, M. G., Alexander, J. L., Ardura, M. I., Miller, T. P., Hijano, D. R., Muller, W. J., Schuster, J. E., Green, A. M., Dulek, D. E., Kajon, A. E. & Danziger-Isakov, L., May 2024, In: Pediatric transplantation. 28, 3, e14750.Research output: Contribution to journal › Article › peer-review
Open Access -
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season
MELODY Study Group, Feb 1 2024, In: Journal of the Pediatric Infectious Diseases Society. 13, 2, p. 144-147 4 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
ROVER Study Investigators, Jul 2024, In: The Lancet Infectious Diseases. 24, 7, p. 687-697 11 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations